Muniz Francisco Wilker Mustafa Gomes, Silva Bernardo Franco da, Goulart Conrado Richel, Silveira Taciane Menezes da, Martins Thiago Marchi
Department of Periodontology, School of Dentistry, Federal University of Pelotas, Rua Gonçalves Chaves, 457, Pelotas, RS, 96015-560, Brazil.
School of Dentistry, Federal University Pelotas, Rua Gonçalves Chaves, 457, Pelotas, RS, 96015-560, Brazil.
J Oral Biol Craniofac Res. 2021 Apr-Jun;11(2):158-168. doi: 10.1016/j.jobcr.2021.01.008. Epub 2021 Jan 21.
Previous systematic reviews showed additional benefit of adjuvant bisphosphonates (BP) in the treatment of periodontitis. In contrast, it is unclear the effect of BP in patients with diabetes and smokers, its pooled effect when administered locally or systemically is also unknown.
This study aimed to systematically review the literature about the use of BP as adjuvant to nonsurgical scaling and root planning (SRP).
This study followed the PRISMA guideline. This study included randomized clinical trials that administered locally or systemically BPs as adjuvant for periodontal treatment. Five databases were used. Meta-analyses were performed, using the pooled mean differences (MD) for clinical attachment level (CAL) and probing pocket depth (PPD). Standard mean difference (SMD) was used for radiographic assessment (RADIO). Subgroup analyses were performed for locally delivered meta-analyses, considering diabetes and smoking exposure.
Thirteen studies were included. It was showed MD of 1.52 mm (95%CI: 0.97-2.07) and 1.44 mm (95%CI: 1.08-1.79) for PPD reduction and CAL gain, respectively, for locally delivered BP. BP was not able to provide significant improvements in smokers (subgroup analysis) when considering CAL (MD: 1.37; 95%CI: -0.17-2.91) and PPD (MD: 1.35; 95%CI: -0.13-2.83). Locally delivered BP also improved significantly the RADIO assessments (SMD: 4.34; 95%CI: 2.94-5.74). MD for systemically administered BP was 0.40 mm (95%CI: 0.21-0.60), 0.51 mm (95%CI: 0.19-0.83) and 1.05 (95%CI: 0.80-1.31) for PPD, CAL and RADIO, respectively.
The administration of BP in adjunct to SRP may result in additional clinical effects.
既往的系统评价显示辅助使用双膦酸盐(BP)治疗牙周炎有额外益处。相比之下,BP对糖尿病患者和吸烟者的影响尚不清楚,其局部或全身给药的综合效果也未知。
本研究旨在系统评价关于使用BP作为非手术龈下刮治和根面平整(SRP)辅助治疗的文献。
本研究遵循PRISMA指南。本研究纳入了将BP局部或全身给药作为牙周治疗辅助手段的随机临床试验。使用了五个数据库。进行荟萃分析,采用临床附着丧失(CAL)和探诊深度(PPD)的合并平均差(MD)。标准化平均差(SMD)用于影像学评估(RADIO)。对局部给药的荟萃分析进行亚组分析,考虑糖尿病和吸烟情况。
纳入13项研究。局部给药BP时,PPD降低和CAL增加的MD分别为1.52毫米(95%CI:0.97 - 2.07)和1.44毫米(95%CI:1.08 - 1.79)。在考虑CAL(MD:1.37;95%CI: - 0.17 - 2.91)和PPD(MD:1.35;95%CI: - 0.13 - 2.83)时,BP对吸烟者(亚组分析)未能带来显著改善。局部给药BP也显著改善了影像学评估(SMD:4.34;95%CI:2.94 - 5.74)。全身给药BP时,PPD、CAL和RADIO的MD分别为0.40毫米(95%CI:0.21 - 0.60)、0.51毫米(95%CI:0.19 - 0.83)和1.05(95%CI:0.80 - 1.31)。
在SRP基础上加用BP可能会产生额外的临床效果。